Lisa Jarvis, Columnist

The Knockoff GLP-1 Market Is Still the Wild West

February 10, 2026 at 12:00 PM UTC

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News.

Do you know what’s in that pill?
Photograph: Novo Nordisk via Bloomberg

Provide news feedback or report an error

Site feedback:

Take our Survey

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

It was an audacious attempt for a piece of the lucrative GLP-1 market that came to a swift and disastrous end — the company pulled its product just two days after its launch after US regulators vowed to take “decisive” action against its knockoff drug and others like it. On Monday, Novo said it was suing Hims over its copycat drugs.